Glioma is the most common primary brain cancer, and half of patients present a diagnosis of glioblastoma (GBM), its most aggressive and lethal form. Conventional therapies, including surgery, radiotherapy, and chemotherapy, have not resulted in major ameliorations in GBM survival outcome, which remains extremely poor. Recent immunotherapy improvements for other tumors, coupled with growing knowledge of the complex interactions between malignant glioma cells and the immune system, led to an exponential increase in glioma immunotherapy research. However, immunotherapeutic strategies in GBM have not yet reached their full potential, mainly due to the limited understanding of the strong immunosuppressive microenvironment (TME) characterizing this tumor. Glioma-associated macrophages and microglia (GAMs) are key drivers of the local immunosuppression promoting tumor progression and its resistance to immunomodulating therapeutic strategies. Together with other myeloid cells, such as dendritic cells and neutrophils, GAMs actively shape glioma TME, modulate anti-tumoral immune response and support angiogenesis, tumor cell invasion and proliferation. In this review, we discuss the role of myeloid cells in the complex TME of glioma and the available clinical data on therapeutic strategies focusing on approaches that affect myeloid cells activity in GBM.

Role of myeloid cells in the immunosuppressive microenvironment in gliomas / C.V. Locarno, M. Simonelli, C. Carenza, A. Capucetti, E. Stanzani, E. Lorenzi, P. Persico, S. Della Bella, L. Passoni, D. Mavilio, R. Bonecchi, M. Locati, B. Savino. - In: IMMUNOBIOLOGY. - ISSN 0171-2985. - 225:1(2020 Jan), pp. 151853.1-151853.11. [10.1016/j.imbio.2019.10.002]

Role of myeloid cells in the immunosuppressive microenvironment in gliomas

C.V. Locarno
Primo
;
M. Simonelli
Secondo
;
C. Carenza;E. Lorenzi;P. Persico;S. Della Bella
Membro del Collaboration Group
;
L. Passoni;D. Mavilio;R. Bonecchi;M. Locati
Penultimo
;
B. Savino
Ultimo
2020-01

Abstract

Glioma is the most common primary brain cancer, and half of patients present a diagnosis of glioblastoma (GBM), its most aggressive and lethal form. Conventional therapies, including surgery, radiotherapy, and chemotherapy, have not resulted in major ameliorations in GBM survival outcome, which remains extremely poor. Recent immunotherapy improvements for other tumors, coupled with growing knowledge of the complex interactions between malignant glioma cells and the immune system, led to an exponential increase in glioma immunotherapy research. However, immunotherapeutic strategies in GBM have not yet reached their full potential, mainly due to the limited understanding of the strong immunosuppressive microenvironment (TME) characterizing this tumor. Glioma-associated macrophages and microglia (GAMs) are key drivers of the local immunosuppression promoting tumor progression and its resistance to immunomodulating therapeutic strategies. Together with other myeloid cells, such as dendritic cells and neutrophils, GAMs actively shape glioma TME, modulate anti-tumoral immune response and support angiogenesis, tumor cell invasion and proliferation. In this review, we discuss the role of myeloid cells in the complex TME of glioma and the available clinical data on therapeutic strategies focusing on approaches that affect myeloid cells activity in GBM.
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
Settore MED/04 - Patologia Generale
Settore MED/06 - Oncologia Medica
Settore MED/26 - Neurologia
Settore MED/27 - Neurochirurgia
19-ott-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Locarno C.V. et all - Immunobiology (On Line Version).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.76 MB
Formato Adobe PDF
1.76 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S0171298519302104-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.66 MB
Formato Adobe PDF
1.66 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/688788
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact